The average one-year price target for Kymera Therapeutics (NasdaqGM:KYMR) has been revised to $111.78 per share, a 41.24% increase from the prior estimate of $79.14 dated December 3, 2025. The new average target indicates a 33.09% rise from the latest reported closing price of $83.99 per share, with analyst targets ranging from $70.70 to $144.90.
Currently, 450 funds report positions in Kymera Therapeutics, with total institutional shares owned increasing by 2.52% to 87.86 million shares. The average portfolio weight allocated to KYMR has risen by 5.29% to 0.39%. The company’s put/call ratio stands at 1.11, suggesting a bearish market outlook.
Among notable shareholders, Baker Bros. Advisors holds 6.65 million shares (8.31% ownership), while Avoro Capital Advisors has reduced its holdings by 3.24% to 6.35 million shares (7.94% ownership). Other significant stakeholders, including Wellington Management and Price T Rowe Associates, reported decreases in their respective allocations over the last quarter.
